<DOC>
	<DOC>NCT01863706</DOC>
	<brief_summary>Post partum Hemorrhage (PPH) is one of three main causes of death in pregnant women. Oxytocin is widely used for prevention of PPH. Some studies suggested misoprostol as an alternative treatment when Oxytocin isn't available. The aim of this study is to compare the safety and efficacy of Oxytocin and misoprostol for prevention of PPH.</brief_summary>
	<brief_title>Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage</brief_title>
	<detailed_description>In a double blind randomized controlled trial 400 pregnant women who has vaginal delivery at Shariati hospital are assigned into two groups either to receive 20 unite oxytocin in 1000cc ringer and 2 placebo tablet or 400mcg oral misoprostol and 2cc normal saline in 1000cc ringer.</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>were women with singleton pregnancy with cephalic presentation who had NVD spontaneously or by induction placenta previa placental detachment coagulation problems previous CS macrosomia Polyhydramnios and uncontrolled asthma</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Misoprostol</keyword>
	<keyword>Oxytocin</keyword>
	<keyword>Post Partum Hemorrhage (PPH)</keyword>
	<keyword>Third stage of labour</keyword>
</DOC>